Michael Leonard Friedlander

机构：Royal Hospital for Women, UNSW Sydney, Prince of Wales Hospital · ORCID：0000-0003-3090-795X

发表论文 935 篇 · 总被引 65072 次 · h-index 102

代表论文

• Olaparib, durvalumab, and cyclophosphamide, and a prognostic blood signature in platinum-sensitive ovarian cancer: the randomized phase 2 SOLACE2 trial (2025 · Nature Communications · 被引 4)
• Long-Term Outcomes in Patients With Recurrent Ovarian Cancer and Exceptional Response to PARP Inhibitors (2026 · JAMA Oncology · 被引 1)
• Clinicopathologic and molecular predictors of survival in BRCA-deficient tubo-ovarian high-grade serous carcinoma (2026 · Nature Communications · 被引 1)
• Time to Treatment Failure as an End Point in Pragmatic Oncology Trials: Association With Progression-Free Survival Across Randomized Studies (2026 · JCO Precision Oncology)
• Enhancing Outcome Measurement in Oncology Clinical Trials Through Artificial Intelligence: A Scoping Review (2026 · JCO Clinical Cancer Informatics)
• Prevalence of clonal hematopoiesis (CH) in BRCA 1/2 mutation carriers enrolled in a randomized prevention trial of acetylsalicylic acid (ASA) – The STICS and STONES study (CCTG-OV25) (2026 · Gynecologic Oncology)